Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma
Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma
Recruiting · NCT06348264 · Registry updated 2025-09-23Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma | Salivary Gland Neoplasm Duct | Recruiting | Phase 2 | 2025-09-23 | NCT06348264 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Beijing Biote Pharmaceutical Co.,Ltd | 1 |
| Jiangsu Hengrui Pharmaceutical Co., Ltd. | 29 |
| Peking University First Hospital | 225 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Peking University First Hospital | Beijing | China | 163 |
| Peking University School and Hospital of Stomatology | Beijing | China | 3 |